Refractory Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
  • Recurrent Alveolar Rhabdomyosarcoma
  • +7 more
  • Birmingham, Alabama
  • +17 more
2022-04-07
Apr 7, 2022
N
Not yet recruiting
  • Advanced Lymphoma
  • +13 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +2 more
  • (no location specified)
2022-03-30
Mar 30, 2022
C
Recruiting
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • +10 more
  • FACT Complex-targeting Curaxin CBL0137
  • Birmingham, Alabama
  • +13 more
2022-03-22
Mar 22, 2022
C
Active, not recruiting
  • Recurrent Lymphoma
  • +5 more
  • Birmingham, Alabama
  • +19 more
2022-03-23
Mar 23, 2022
C
Active, not recruiting
  • Malignant Glioma
  • +9 more
  • Birmingham, Alabama
  • +22 more
2022-02-11
Feb 11, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Afatinib Dimaleate
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Trametinib Dimethyl Sulfoxide
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Trastuzumab Emtansine
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • PI3K-beta Inhibitor GSK2636771
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +4 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Dabrafenib Mesylate
  • Trametinib Dimethyl Sulfoxide
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Trametinib Dimethyl Sulfoxide
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Defactinib Hydrochloride
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • PI3K-beta Inhibitor GSK2636771
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
N
Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2022-02-04
Feb 4, 2022
M
Recruiting
  • Leukemia
  • +5 more
  • Next Generation Sequencing
  • Munich, Germany
    MLL Munich Leukemia Laboratory
2022-01-19
Jan 19, 2022
N
Completed
  • Brain Stem Neoplasm
  • +9 more
  • Birmingham, Alabama
  • +20 more
2021-10-06
Oct 6, 2021